Micardis, Kinzalmono, Pritor, Telmisartan Boehringer Ingelheim Pharma KG (telmisartan) is a small molecule pharmaceutical. Telmisartan was first approved as Micardis on 1998-11-10. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. It has been approved in Europe to treat hypertension. The pharmaceutical is active against type-1 angiotensin II receptor. In addition, it is known to target peroxisome proliferator-activated receptor gamma. Micardis's patent is valid until 2022-10-06 (FDA).
|Trade Name||Kinzalmono, Micardis, Pritor, Telmisartan Boehringer Ingelheim Pharma KG|
|Indication||diabetic nephropathies, heart failure, hypertension, left ventricular dysfunction|
|Drug Class||Angiotensin II receptor antagonists|